ArticleAging cell2026
Senescent Fibroblasts Impair B Cell Proliferation via Cell-Cell Contact.
Article in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ageing profoundly impairs vaccine efficacy, leaving older individuals highly susceptible to infectious diseases despite vaccination. Although B cells retain the intrinsic capacity to generate germinal centre (GC) responses in older people, age-associated defects in T cells, dendritic cells and follicular dendritic cells (FDCs) limit the development of high-affinity, class-switched antibody responses. Here, we hypothesised that senescent fibroblasts disrupt B cell activation and expansion, thus contributing to the diminution of the humoral response in ageing. To test this hypothesis, we established an in vitro system in which human tonsil-derived YK6 fibroblasts expressing CD40L are co-cultured with PBMC-derived B cells. B cell activation, proliferation, and phenotype in response to low- and high-stimulation conditions was determined in co-culture with control or bleomycin-treated YK6 fibroblasts. Control YK6 fibroblasts promoted B-cell activation and proliferation in both 2D and 3D cultures, whereas bleomycin-treated fibroblasts robustly inhibited B-cell proliferation without impairing early activation. Conditioned media from bleomycin-treated fibroblasts partially reduced B cell proliferation, although to a lesser extent than direct co-culture, suggesting cell-cell contact was key to inhibiting B cell proliferation. Bleomycin-treated YK6 fibroblasts upregulated genes associated with impaired lymphocyte responses, such as PDCD1LG2, which may impact B cell activation. Indeed, B cells co-cultured with bleomycin-treated fibroblasts failed to fully initiate glycolysis and were essentially unable to synthesise new protein. Together, these findings suggest that senescence-like changes in fibroblasts could restrict B-cell proliferative capacity, which may contribute to impaired B cell responses in ageing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.